Drugs / PF-05019702
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00543790 | Nov 2007 → Dec 2008 | uterine corpus leiomyoma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00444704 | Mar → Dec 2007 | leiomyoma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00427544 | Feb → Aug 2007 | leiomyoma | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-05019702 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545239 ↗ |
| Known as | PRA-027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00427544 ↗ |
| Known as | WAY-257027 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545239 ↗ |
| Action | Inhibit | “Progesterone receptor antagonist” CHEMBL3545239 ↗ |
| Route | Oral | “administered orally” NCT00427544 ↗ |
| Target | PGR | “Progesterone receptor antagonist” CHEMBL3545239 ↗ |